| 吴素素,冯 雁,罗小玲.免疫检查点抑制剂治疗晚期肝细胞癌的临床研究进展[J].中国肿瘤,2019,28(10):780-785. |
| 免疫检查点抑制剂治疗晚期肝细胞癌的临床研究进展 |
| Progress in Clinical Research of Immunological Checkpoint Inhibitors in Treatment of Advanced Hepatocellular Carcinoma |
| 投稿时间：2019-06-02 |
| DOI：10.11735/j.issn.1004-0242.2019.10.A011 |
|
 |
| 中文关键词: 肝细胞癌 免疫治疗 免疫检查点抑制剂 |
| 英文关键词:hepatocellular carcinoma immunotherapy immunological checkpoint inhibitor |
| 基金项目:国家自然科学基金（81560493，81860504）；广西自然科学基金（2015GXNSFDA139024）；广西自然科学基金青年基金（2018GXNBFBA138033） |
|
| 摘要点击次数: 1716 |
| 全文下载次数: 498 |
| 中文摘要: |
| 摘 要：肝细胞癌（HCC）是发病率最高的恶性肿瘤之一，也是癌症相关死亡的主要原因。免疫检查点抑制剂（immune checkpoint inhibitor，ICI）用于肿瘤治疗近年来发展迅速。多项临床研究已经显示以PD-1/PD-L1和CTLA-4抑制剂为代表的ICIs在晚期HCC中有良好的治疗效果。然而，近年来的临床研究证明并非所有患者都能从ICIs中获益。全文针对ICIs在治疗晚期HCC的临床研究及优势人群的筛选研究进展进行综述。 |
| 英文摘要: |
| Abstract：Globally，hepatocellular carcinoma(HCC) is one of the most common malignancies and the leading causes of cancer-related deaths. Immunological checkpoint inhibitors(ICI) have developed rapidly in recent years. Several ongoing clinical studies have proved the effect of ICIs including PD-1/PD-L1 and CTLA-4 inhibitors in treatment of advanced HCC. However，these studies also revealed that not all patients could be benefited from ICIs treatment.This article summarizes the recent progress of clinical researches on ICIs in treatment of advanced HCC patients and the biomarkers for screening of patients who may be benefited from ICI therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |